Anlotinib Retrospective Study for Esophageal Cancer

Feng Wang300 enrolled

Overview

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Esophageal Neoplasms

Interventions

AnlotinibDRUG

This is an observational study.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Esophageal cancer diagnosed pathologically or clinically * Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment Exclusion Criteria: None

Locations (1)

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Outcomes

Primary Outcomes

PFS

Progression Free Survival

Time frame: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Secondary Outcomes

Overall Survival

Time frame: From date of admission until the date of death from any cause, assessed up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.